Novo Nordisk A/S

자세한 내용은 Novo Nordisk A/S 회사

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

회사 정보

종목 코드 NVO

회사 이름Novo Nordisk A/S

상장일May 17, 1974

CEOMr. Maziar Mike Doustdar

직원 수76302

유형Ordinary Share

회계 연도 종료May 17

주소Novo Alle 1

도시BAGSVAERD

증권 거래소The Toronto Stock Exchange

국가Denmark

우편 번호2880

전화4544448888

웹사이트https://www.novonordisk.com/

종목 코드 NVO

상장일May 17, 1974

CEOMr. Maziar Mike Doustdar

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Emil Kongshoj Larsen

Executive Vice President - International Operations

--

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Ms. Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Mr. Thomas Rantzau

Director, Employee Representative

--

Ms. Tania Sabroe

Executive Vice President - People, Organisation & Corporate Affairs

--

Dr. Martin Holst Lange

Executive Vice President, Chief Scientific Officer, Research & Development

--

Mr. Andreas Fibig

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Emil Kongshoj Larsen

Executive Vice President - International Operations

--

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Ms. Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Total GLP-1

5.58B

50.68%

Long-acting insulin

759.51M

6.90%

Fast-acting insulin

712.15M

6.47%

Rare blood disorders

411.75M

3.74%

Premix insulin

396.53M

3.60%

Other

3.15B

28.61%

지역별USD

이름

수익

비율

USA

6.25B

56.75%

Canada

2.08B

18.91%

Emerging Markets

1.24B

11.26%

Region China

792.49M

7.20%

APAC

647.58M

5.88%

사업별

지역별

사업별USD

이름

수익

비율

Total GLP-1

5.58B

50.68%

Long-acting insulin

759.51M

6.90%

Fast-acting insulin

712.15M

6.47%

Rare blood disorders

411.75M

3.74%

Premix insulin

396.53M

3.60%

Other

3.15B

28.61%

주식 보유 통계

마지막 업데이트: Sat, Aug 2

주주

주주 유형

주주

비율

Jennison Associates LLC

0.56%

Loomis, Sayles & Company, L.P.

0.37%

Fisher Investments

0.35%

Fayez Sarofim & Co.

0.33%

Folketrygdfondet

0.28%

Other

98.10%

주주

비율

Jennison Associates LLC

0.56%

Loomis, Sayles & Company, L.P.

0.37%

Fisher Investments

0.35%

Fayez Sarofim & Co.

0.33%

Folketrygdfondet

0.28%

Other

98.10%

주주 유형

주주

비율

Investment Advisor

4.82%

Investment Advisor/Hedge Fund

2.68%

Research Firm

0.84%

Hedge Fund

0.78%

Pension Fund

0.30%

Insurance Company

0.19%

Bank and Trust

0.17%

Family Office

0.02%

Family Office

0.02%

Other

90.18%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

2754

330.35M

9.82%

-31.19M

2025Q1

2769

336.08M

9.99%

-21.71M

2024Q4

2676

348.53M

10.35%

+330.19K

2024Q3

2529

339.29M

10.15%

-6.04M

2024Q2

2456

341.24M

10.21%

+6.87M

2024Q1

2291

330.25M

9.75%

+10.89M

2023Q4

2037

314.57M

9.30%

+1.47M

2023Q3

1826

307.14M

8.91%

+4.22M

2023Q2

1692

293.83M

8.50%

+768.69K

2023Q1

1603

284.38M

8.30%

-15.92M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Jennison Associates LLC

18.82M

0.56%

-1.12M

-5.63%

Mar 31, 2025

Loomis, Sayles & Company, L.P.

12.39M

0.37%

+816.56K

+7.06%

Mar 31, 2025

Fisher Investments

11.87M

0.35%

-769.25K

-6.09%

Mar 31, 2025

Fayez Sarofim & Co.

11.21M

0.33%

-171.98K

-1.51%

Mar 31, 2025

Folketrygdfondet

9.52M

0.28%

+617.97K

+6.94%

Mar 31, 2025

Capital International Investors

9.51M

0.28%

+2.76M

+40.82%

Mar 31, 2025

Fidelity Management & Research Company LLC

8.98M

0.27%

-907.73K

-9.18%

Mar 31, 2025

Managed Account Advisors LLC

8.61M

0.26%

-774.82K

-8.25%

Mar 31, 2025

Two Sigma Investments, LP

8.00M

0.24%

+5.13M

+178.84%

Mar 31, 2025

Renaissance Technologies LLC

6.82M

0.2%

-1.49M

-17.94%

Mar 31, 2025

49.825USD

Novo Nordisk A/S

49.825

개요

회사

금융